Pathstone Family Office, LLC Regeneron Pharmaceuticals, Inc. Transaction History

Pathstone Family Office, LLC

$15.6 Billion
Q3 2023

A detailed history of Pathstone Family Office, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Pathstone Family Office, LLC holds 5,649 shares of REGN stock, worth $5.79 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

5,649

Previous 3,266 72.96%

Holding current value

$5.79 Million

Previous $2.35 Million 98.12%

% of portfolio

0.03%

Previous 0.04%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 08, 2023	BUY	$692.45 - $844.37 $1.65 Million - $2.01 Million	2,383 Added 72.96%	5,649 $4.65 Million
Q2 2023 Jan 12, 2024	SELL	$700.03 - $830.35 $1.67 Million - $1.98 Million	-2,383 Reduced 42.18%	3,266 $2.35 Million
Q2 2023 Aug 14, 2023	BUY	$700.03 - $830.35 $70,003 - $83,035	100 Added 3.16%	3,266 $2.35 Million
Q1 2023 May 15, 2023	SELL	$680.49 - $826.97 $783,924 - $952,669	-1,152 Reduced 26.68%	3,166 $2.6 Million
Q4 2022 Oct 23, 2023	BUY	$705.89 - $766.39 $768,008 - $833,832	1,088 Added 33.68%	4,318 $3.12 Million

Q4 2022 Feb 13, 2023	BUY	$705.89 - $766.39 $103,059 - $111,892	146 Added 3.5%	4,318 $3.12 Million
Q3 2022 Oct 23, 2023	BUY	$573.97 - $724.32 $1.19 Million - $1.5 Million	2,077 Added 180.14%	3,230 $2.23 Million
Q3 2022 Nov 14, 2022	BUY	$573.97 - $724.32 $1.29 Million - $1.62 Million	2,243 Added 116.28%	4,172 $2.9 Million
Q2 2022 Oct 23, 2023	SELL	$548.35 - $738.84 $1.16 Million - $1.56 Million	-2,113 Reduced 64.7%	1,153 $681,000
Q2 2022 Aug 15, 2022	BUY	$548.35 - $738.84 $447,453 - $602,893	816 Added 73.32%	1,929 $1.14 Million
Q1 2022 May 16, 2022	BUY	$595.12 - $698.43 $50,585 - $59,366	85 Added 8.27%	1,113 $802,000
Q4 2021 Feb 14, 2022	BUY	$543.48 - $670.97 $300,000 - $370,375	552 Added 115.97%	1,028 $649,000
Q3 2021 Nov 16, 2021	SELL	$574.03 - $680.96 $20,091 - $23,833	-35 Reduced 6.85%	476 $288,000
Q2 2021 Aug 31, 2021	BUY	$472.8 - $558.54 $2,836 - $3,351	6 Added 1.19%	511 $285,000
Q1 2021 May 14, 2021	BUY	$446.73 - $548.2 $71,923 - $88,260	161 Added 46.8%	505 $239,000
Q4 2020 Feb 16, 2021	BUY	$478.3 - $607.98 $115,748 - $147,131	242 Added 237.25%	344 $166,000
Q2 2020 Aug 14, 2020	SELL	$493.32 - $643.92 $9,866 - $12,878	-20 Reduced 16.39%	102 $63,000
Q1 2020 Jun 11, 2020	BUY	$336.18 - $494.43 $40,341 - $59,331	120 Added 6000.0%	122 $60,000
Q1 2020 May 07, 2020	SELL	$336.18 - $494.43 $45,720 - $67,242	-136 Reduced 98.55%	2 $977,000
Q4 2019 Feb 14, 2020	BUY	$274.13 - $376.51 $10,416 - $14,307	38 Added 38.0%	138 $518,000
Q2 2019 Aug 14, 2019	SELL	$299.6 - $414.82 $6,291 - $8,711	-21 Reduced 17.36%	100 $31,000
Q1 2019 May 14, 2019	BUY	$372.08 - $439.57 $37,208 - $43,957	100 Added 476.19%	121 $50,000
Q4 2018 Feb 14, 2019	BUY	$335.82 - $403.04 $7,052 - $8,463	21 New	21 $8,000

Others Institutions Holding REGN

# of Institutions

1,427

Shares Held

82.1M

Call Options Held

835K

Put Options Held

1.46M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $110B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pathstone Family Office, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pathstone Family Office, LLC with notifications on news.

Account

Pathstone Family Office, LLC Regeneron Pharmaceuticals, Inc. Transaction History